Radiopharm Theranostics Limited American Depositary Shares Cash Flow Conversion Efficiency
Radiopharm Theranostics Limited American Depositary Shares cash flow conversion efficiency. Based on the latest financial reports, Radiopharm Theranostics Limited American Depositary Shares (RADX) has a cash flow conversion efficiency ratio of -1.437x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-32.08 Million) by net assets ($22.32 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Radiopharm Theranostics Limited American Depositary Shares (2022–2026)
Cash flow conversion efficiency of Radiopharm Theranostics Limited American Depositary Shares from 2022 to 2026. This chart illustrates how Radiopharm Theranostics Limited American Depositary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Radiopharm Theranostics Limited American share price for real-time trading data and today's change.
Radiopharm Theranostics Limited American Depositary Shares Cash Flow Conversion Ratio Explained
Radiopharm Theranostics Limited American Depositary Shares cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Radiopharm Theranostics Limited American Depositary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Radiopharm Theranostics Limited American Depositary Shares ranked by their cash flow conversion efficiency. Also see RADX stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Donegal Investment Group PLC
IR:DQ7A
|
-0.234x |
|
HWH International Inc
NASDAQ:HWH
|
0.171x |
|
Ping An Biomedical Co., Ltd.
NASDAQ:PASW
|
N/A |
|
TRC Construction Public Company Limited
BK:TRC
|
0.069x |
|
Pointerra Ltd
AU:3DP
|
2.015x |
|
Moatech Co. Ltd
KQ:033200
|
0.005x |
|
Cashlez Worldwide Indonesia Tbk
JK:CASH
|
0.596x |
|
KR Motors Co. Ltd.
KO:000040
|
0.032x |
Annual Cash Flow Conversion Efficiency for Radiopharm Theranostics Limited American Depositary Shares (2022–2026)
The table below shows the annual cash flow conversion efficiency of Radiopharm Theranostics Limited American Depositary Shares from 2022 to 2026. Review financial agility of Radiopharm Theranostics Limited American to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-06-30 | $22.32 Million | $-51.63 Million | -2.313x | -170.56% |
| 2025-06-30 | $42.87 Million | $-36.65 Million | -0.855x | -1.76% |
| 2024-06-30 | $27.35 Million | $-22.98 Million | -0.840x | -65.01% |
| 2023-06-30 | $45.58 Million | $-23.20 Million | -0.509x | -223.23% |
| 2022-06-30 | $62.96 Million | $-9.92 Million | -0.157x | -- |
About Radiopharm Theranostics Limited American Depositary Shares
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; R… Read more